Table 2

 Demographic, clinical, and biological data on 13 patients treated with rituximab for systemic lupus erythematosus

CaseSex/age/duration (y)No of prior IS/prior CPH (Y/N)Clinical involvementNo of infusions × dose (mg)/No of MP pulses/concomitant ISAdverse event (Y/N)Efficacy (Y/N)Time to response (w)/follow up (m)SLEDAI initial/last†Prednisone initial/last (mg/d)‡Anti-dsDNA IgG initial/last ELISA (IU/ml) (n <20)C3 and/or C4 normalisation (Y/N)Relapse (Y/N)/time to relapse (m)
*Farr’s test (n <7).
†p<0.0002 between SLEDAI value pre- and post-treatment using paired t test.
‡p<0.01 between prednisone dose pre- and post-treatment.
§Marked improvement in digital angiitis was observed and proteinuria resolved.
APS, antiphospholipid syndrome; AZA, azathioprine; CIC, ciclosporine; CNS, central nervous system; CPH, cyclophosphamide; ELISA, enzyme linked immunosorbent assay; F, female; HQ, hydroxychloroquine; IS, immunosuppressants; ivIg, intravenous immunoglobulin; m, months; M, male; MMF, mycophenolate mofetil; MP, methylprednisolone; MTX, methotrexate; N, no; NA, not available; neg, negative; plasmaph, plasmapheresis; pos, positive; SLEDAI, SLE disease activity index; w, weeks; y, years; Y, yes; –, not relevant.
15F/30/31/NPleuropericarditis1×375.m−2NeutropeniaN–/68/625/2540/neg*N
16M/20/73/YNephritis/myocarditis/Evans4×375.m−2NY2/1518/660/10144/10*YY/15
17F/55/82/NAutoimmune haemolytic anaemia, lymphadenopathy4×375.m−2/2/MP (80)/ivIgNDeath–/28/NA60/15Neg/negN
18M/21/32/YCNS (psychosis)4×375.m−2NY12/269/250/225/neg*YN
19F/26/103/NSkin, articular4×375.m−2NY4/66/030/699/0YN
20F/41/52/NArticular4×375.m−2/AZANY1/76/25/2Neg/negNAN
21F/30/133/YArticular, vasculitis, nephritis4×375.m−2/HQDeep vein thrombosisN–/528/2050/15100–500N
22F/28/192/YSkin, articular4×375.m−2Serum sickness, pulmonary embolismY4/46/214/131280–320NN
23M/33/95/YAutoimmune thrombocytopenia, nephritis4×375.m−2/CICNY8/98/230/10NA/31YY/9
24F/28/183/NAutoimmune thrombocytopenia, APS3×375.m−2/AZASerum sicknessY4/103/230/10300/286NN
25F/28/23/YNephritis, thrombotic microangiopathy4×375.m−2/plasmaph/CPHNDeath–/224/NA60/60113/NAN
26F/22/33/YArticular4×375.m−2/2/MP (80)/MMFNeutropeniaY6/79/012.5/10199/negYN
27F/30/202/NArticular, vasculitis4×375 msNY4/418/14§9/850/75NN